HRP20190907T1 - Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) - Google Patents
Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) Download PDFInfo
- Publication number
- HRP20190907T1 HRP20190907T1 HRP20190907TT HRP20190907T HRP20190907T1 HR P20190907 T1 HRP20190907 T1 HR P20190907T1 HR P20190907T T HRP20190907T T HR P20190907TT HR P20190907 T HRP20190907 T HR P20190907T HR P20190907 T1 HRP20190907 T1 HR P20190907T1
- Authority
- HR
- Croatia
- Prior art keywords
- mutant
- leukocidin
- subunit
- tag
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 15
- 229920001184 polypeptide Polymers 0.000 title claims 11
- 230000002163 immunogen Effects 0.000 title claims 2
- 108010078471 Panton-Valentine leukocidin Proteins 0.000 title 1
- 108010014603 Leukocidins Proteins 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 102000028861 calmodulin binding Human genes 0.000 claims 2
- 108091000084 calmodulin binding Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims 1
- 108050001427 Avidin/streptavidin Proteins 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 108010090623 galactose binding protein Proteins 0.000 claims 1
- 102000021529 galactose binding proteins Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 101150066555 lacZ gene Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 101150044170 trpE gene Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Izolirani mutant polipeptida divljeg tipa stafilokokne podjedinice leukocidina koji sadrži SEQ ID NO: 5, 6 ili 15,
naznačen time što mutant polipeptida stafilokokne podjedinice leukocidina sadrži aminokiselinsku supstituciju na položaju koji odgovara K97 u SEQ ID NO: 6
što smanjuje toksičnost mutanta podjedinice leukocidina u odnosu na odgovarajuću podjedinicu divljeg tipa leukocidina;
ili
izolirani mutant polipeptida divljeg tipa stafilokokne podjedinice leukocidina koji sadrži SEQ ID NO: 16, 17, 21, 22, 23, 24, 25 ili 26,
pri čemu mutant stafilokokne podjedinice leukocidina sadrži aminokiselinsku supstituciju na položaju koji odgovara K102 u SEQ ID NO: 17,
što smanjuje toksičnost mutanta podjedinice leukocidina u odnosu na odgovarajuću podjedinicu divljeg tipa leukocidina.
2. Mutantna podjedinica leukocidina prema zahtjevu 1, naznačena time što je položaj koji odgovara K97 u SEQ ID NO: 6 ili K102 u SEQ ID NO: 17 supstituiran s alaninom.
3. Mutantna podjedinica leukocidina prema zahtjevu 1 ili 2, naznačena time što mutant podjedinice leukocidina je Panton-Valentin leukocidin (PVL) LukS-PV koji sadrži sekvencu aminokiseline SEQ ID NO: 7 ili 14 ili pri čemu je mutant podjedinice leukocidina Panton-Valentin leukocidin (PVL) LukF-PV koji sadrži sekvencu aminokiseline SEQ ID NO: 18 ili 136.
4. Polipeptidni kompleks naznačen time što sadrži mutant podjedinice leukocidina prema bilo kojem od zahtjeva 1 do 3 ili njihovu kombinaciju.
5. Mutantna podjedinica leukocidina prema bilo kojem od zahtjeva 1 do 3, naznačena time što nadalje sadrži heterolognu sekvencu aminokiseline.
6. Mutantna podjedinica leukocidina prema zahtjevu 5, naznačena time što heterologna sekvenca aminokiseline kodira:
(a) peptid odabran iz skupine koja sadrži His-oznaku, ubikvitin oznaku, NusA oznaku, hitin vezujuću domenu, B-oznaku, HSB-oznaku, zeleni fluorescentni protein (GFP), protein koji veže kalmodulin (CBP), galaktoza-vezujući protein, maltoza-vezujući protein (MBP), domene koje vežu celulozu (CBD), avidin/streptavidin/Strep-oznaku, trpE, kloramfenikol acetiltransferazu, lacZ(β-Galaktozidazu), FLAG™ peptid, S-oznaku, T7-oznaku, odsječak bilo kojeg od navedenih heterolognih peptida, i kombinaciju dva ili više navedenih heterolognih peptida; ili
(b) pri čemu heterologna sekvenca aminokiseline kodira imunogen, epitop T-stanica, epitop B-stanica, odsječak bilo kojeg od navedenih heterolognih peptida, i kombinaciju dva ili više navedenih heterolognih peptida.
7. Izolirani polinukleotid naznačen time što sadrži nukleinsku kiselinu koja kodira podjedinicu mutantnog leukocidina iz bilo kojeg od patentnih zahtjeva 1-3 ili 5-6.
8. Vektor naznačen time što sadrži polinukleotid prema zahtjevu 7.
9. Stanica domaćin, naznačena time što sadrži polinukleotid prema zahtjevu 7 ili vektor prema zahtjevu 8.
10. Postupak dobivanja polipeptida mutirane stafilokokne podjedinice leukocidina, naznačen time što sadrži kultiviranje stanice domaćina prema zahtjevu 9, te obnavljanje polipeptida.
11. Pripravak naznačen time što sadrži mutantnu podjedinicu leukocidina prema bilo kojem od zahtjeva 1-3 ili 5-6, ili polipeptidni kompleks prema zahtjevu 4, te nosač.
12. Pripravak prema zahtjevu 11 naznačen time što se koristi u postupku induciranja imunog odgovora domaćina protiv soja Staphylococcus aureus , koji se sastoji od primjene djelotvorne količinu navedenog pripravka na subjekta kojem je potreban imunološki odgovor.
13. Pripravak koji sadrži mutantnu podjedinicu leukocidina prema bilo kojem od zahtjeva 1 do 3 ili 5 do 6, ili polipeptidni kompleks prema zahtjevu 4, naznačen time što je namijenjen upotrebi u postupku prevencije ili liječenja stafilokokne bolesti ili infekcije kod subjekta koji se sastoji od davanja pripravka subjektu kojem je to potrebno.
14. Postupak za proizvodnju cjepiva protiv infekcije S. aureus naznačen time što sadrži:
(a) izoliranje mutantne podjedinice leukocidina prema bilo kojem od zahtjeva 1-3 ili 5-6 ili polipeptidnog kompleksa prema zahtjevu 4; i
(b) kombiniranje mutantne podjedinice leukocidina ili polipeptidnog kompleksa s pomoćnim sredstvom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566234P | 2011-12-02 | 2011-12-02 | |
| PCT/US2012/067483 WO2013082558A1 (en) | 2011-12-02 | 2012-11-30 | Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides |
| EP12854165.3A EP2785368B1 (en) | 2011-12-02 | 2012-11-30 | Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190907T1 true HRP20190907T1 (hr) | 2019-07-12 |
Family
ID=48536149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190907TT HRP20190907T1 (hr) | 2011-12-02 | 2019-05-16 | Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10023848B2 (hr) |
| EP (1) | EP2785368B1 (hr) |
| JP (1) | JP6325452B2 (hr) |
| KR (1) | KR101999299B1 (hr) |
| AU (1) | AU2012345645B2 (hr) |
| CA (1) | CA2857666C (hr) |
| DK (1) | DK2785368T3 (hr) |
| ES (1) | ES2728445T3 (hr) |
| HR (1) | HRP20190907T1 (hr) |
| LT (1) | LT2785368T (hr) |
| RS (1) | RS58919B1 (hr) |
| SI (1) | SI2785368T1 (hr) |
| WO (1) | WO2013082558A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101999299B1 (ko) | 2011-12-02 | 2019-07-12 | 인티그레이티드 바이오쎄라퓨틱스, 인크. | 팬턴-발렌타인 류코시딘(pvl) 유래 폴리펩티드를 포함하는 면역원성 조성물 |
| JP2016528185A (ja) | 2013-06-18 | 2016-09-15 | ニューヨーク・ユニバーシティ | 黄色ブドウ球菌ロイコシジンの細胞毒性に関与する細胞因子：新規治療標的 |
| CA2916231C (en) | 2013-06-19 | 2024-02-06 | Integrated Biotherapeutics, Inc. | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
| US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| BR112016008275A2 (pt) * | 2013-10-17 | 2017-10-03 | Arsanis Biosciences Gmbh | Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora |
| AU2016304671A1 (en) * | 2015-08-10 | 2018-02-22 | Kyoto Biken Laboratories, Inc. | Vaccine obtained by mixing inactivated staphylococcus aureus and leukocidin |
| CN107224575B (zh) * | 2017-03-06 | 2018-11-09 | 浙江海隆生物科技有限公司 | 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用 |
| CA3069747A1 (en) | 2017-07-27 | 2019-01-31 | Mohammad Javad Aman | Immunogenic composition comprising a fusion peptide derived from superantigen toxoids |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US20100158871A1 (en) | 1999-08-30 | 2010-06-24 | David Stephen Terman | Sickled erythrocytes with antitumor molecules induce tumoricidal effects |
| US20050008633A1 (en) | 2003-05-19 | 2005-01-13 | Advanced Inhalation Research Inc. | Chemical and physical modulators of bioavailability of inhaled compositions |
| MX2007015758A (es) * | 2005-06-13 | 2008-02-22 | Nabi Biopharmaceuticals | Uso de leucocidina de panton-valentine para tratar y prevenir infecciones por estafilococos. |
| US7754225B2 (en) | 2006-07-20 | 2010-07-13 | Glaxosmithkline Biologicals S.A. | Method of protecting against staphylococcal infection |
| WO2008050041A1 (fr) * | 2006-10-18 | 2008-05-02 | Biomerieux | Procede de diagnostic in vitro des staphylococcus aureus producteurs de pvl |
| KR101999299B1 (ko) | 2011-12-02 | 2019-07-12 | 인티그레이티드 바이오쎄라퓨틱스, 인크. | 팬턴-발렌타인 류코시딘(pvl) 유래 폴리펩티드를 포함하는 면역원성 조성물 |
-
2012
- 2012-11-30 KR KR1020147018356A patent/KR101999299B1/ko active IP Right Grant
- 2012-11-30 JP JP2014544964A patent/JP6325452B2/ja active Active
- 2012-11-30 RS RS20190664A patent/RS58919B1/sr unknown
- 2012-11-30 WO PCT/US2012/067483 patent/WO2013082558A1/en active Application Filing
- 2012-11-30 LT LTEP12854165.3T patent/LT2785368T/lt unknown
- 2012-11-30 DK DK12854165.3T patent/DK2785368T3/da active
- 2012-11-30 US US14/362,298 patent/US10023848B2/en active Active
- 2012-11-30 CA CA2857666A patent/CA2857666C/en active Active
- 2012-11-30 ES ES12854165T patent/ES2728445T3/es active Active
- 2012-11-30 AU AU2012345645A patent/AU2012345645B2/en active Active
- 2012-11-30 SI SI201231603T patent/SI2785368T1/sl unknown
- 2012-11-30 EP EP12854165.3A patent/EP2785368B1/en active Active
-
2019
- 2019-05-16 HR HRP20190907TT patent/HRP20190907T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2785368A1 (en) | 2014-10-08 |
| JP6325452B2 (ja) | 2018-05-16 |
| US20140308291A1 (en) | 2014-10-16 |
| LT2785368T (lt) | 2019-06-10 |
| CA2857666A1 (en) | 2013-06-06 |
| EP2785368B1 (en) | 2019-03-13 |
| US10023848B2 (en) | 2018-07-17 |
| JP2015505831A (ja) | 2015-02-26 |
| CA2857666C (en) | 2020-08-11 |
| AU2012345645B2 (en) | 2017-09-07 |
| AU2012345645A1 (en) | 2014-06-26 |
| KR20140117381A (ko) | 2014-10-07 |
| EP2785368A4 (en) | 2015-12-30 |
| WO2013082558A1 (en) | 2013-06-06 |
| ES2728445T3 (es) | 2019-10-24 |
| NZ626762A (en) | 2016-07-29 |
| DK2785368T3 (da) | 2019-05-27 |
| KR101999299B1 (ko) | 2019-07-12 |
| SI2785368T1 (sl) | 2019-08-30 |
| RS58919B1 (sr) | 2019-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190907T1 (hr) | Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) | |
| HRP20191902T1 (hr) | Antigeni virusa ljudske imunodeficijencije, vektori, pripravci, i postupci njihove upotrebe | |
| JP7094103B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| DK2445526T3 (en) | Recombinant RSV antigens. | |
| CA2710600C (en) | Recombinant rsv antigens | |
| HRP20170094T1 (hr) | Imunogeni pripravak | |
| Sereinig et al. | Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge | |
| RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
| Yadav et al. | Characterization of immune response elicited by the recombinant outer membrane protein OmpF of Aeromonas hydrophila, a potential vaccine candidate in murine model | |
| PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
| Zhou et al. | A novel multivalent vaccine based on secretary antigen-delivery induces protective immunity against Vibrio anguillarum and Aeromonas hydrophila | |
| JP2009540801A5 (hr) | ||
| JP2010535026A5 (hr) | ||
| EP3166962A1 (en) | Influenza virus vaccines and uses thereof | |
| JP2014507146A5 (hr) | ||
| US20160122398A1 (en) | Recombinant rsv antigens | |
| WO2008127179A8 (en) | Fusion protein vaccine | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| WO2019006401A3 (en) | LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF | |
| IL294797A (en) | Influenza virus vaccines and their uses | |
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| WO2018172259A3 (en) | IMPROVED LI VACCINE ADJUVANT | |
| HRP20220064T1 (hr) | Zglobno modificirani fragmenti protutijela i postupci za pripravu | |
| WO2013171661A3 (en) | Adjuvant formulations and methods |